Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Dismay as NICE rejects Roche’s MS drug Ocrevus
such as Novartis’Gilenya (fingolimod) and Biogen’s Tecfidera (dimethyl fumarate).
Latest news
-
Pfizer abandons antibody for Duchenne
The failure of domagrozumab to move the needle in DMD could also give other companies developing myostatin-targeted therapies the jitters, including Biogen which has just agreed a $535m licensing deal ... Biogen is however focusing initially on spinal
-
Roche highlights Hemlibra data as key FDA date approaches
every few days, such as Shire’s Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla, uptake hasn’t been as quick as hoped.
-
Shock as NICE turns down Biogen’s SMA therapy
Shock as NICE turns down Biogen’ s SMA therapy. UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear. ... NICE is open to the idea of a temporary managed access agreement (MAA) but according to the charity has described
-
Mallinckrodt doses first patient in muscular dystrophy trial
Other therapeutic approaches under test for DMD include gene-editing with CRISPR/Cas9, myostatin inhibitors from Pfizer, Bristol-Myers Squibb and Biogen/AliveGen, and Santhera’s antioxidant idebenone, which like
-
Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate
Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full approval last year, while Sandoz (a Novartis division) has also just gained approval for its biosimilar, to be ... Amgen, Samsung/Biogen and Sandoz.
More from news
Approximately 97 fully matching, plus 272 partially matching documents found.
Latest Intelligence
-
No incentive for a cure
to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.
-
Deal Watch January 2018
Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound
-
The good, the bad and the ugly
Biogen was the largest seller in the CNS market in 2017 and this is forecast to continue, ”says Rahael Maladwala, analyst, neurology and ophthalmology, GlobalData. ... Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales
-
Simplifying HCP access to digital information
Biogen, one of Align Biopharma’s founding members. ... Other founding members include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis and Pfizer.
-
Managing medication non-adherence
efficacious. Biogen has been playing in this space for a few years now and conducted a clinical trial with PatientsLikeMe that showed how people living with multiple sclerosis (MS) can use
More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.
Latest appointments
-
BMS appoints CCO, Stephen Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has experience with following his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Pegasus shortlisted for four PM Society Digital Media Awards 2016
four awards at the PM Society Digital Media Awards 2016 for its ‘ MS Explorer’ exhibit stand installation for Biogen, and 'Beatbox Cough' campaign for Boehringer Ingelheim and the Roy Castle Lung ... As a leader in multiple sclerosis (MS) treatment,
-
It's time to change the conversation
This is due in a large part to Biogen’ s approach and leadership in the treatment of the disease. ... to patient information.Biogen changed the conversation about the disease as well as the conversation with patients.
-
It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016
Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’ s MS Explorer, and two silvers ... As a leader in multiple sclerosis (MS) treatment,
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
-
Bedrock Healthcare Communications
Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Featured jobs
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
-
Sudler London - Account Director
-
Competitive
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
wethepeople
wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
